Biobizkaia Health Research Institute
If you are the contact person for this centre and you wish to make any changes, please contact us.
Coordinator of Colorectal and prenatal cancer screening at the Basque Health Service-Osakidetza, researcher in the Cancer Biomarkers group at the Biobizkaia Health Research Institute and secretary of the Board of Directors of the Spanish Society of Epidemiology
A team of researchers has analyzed data from the World Health Organization to estimate the incidence of colorectal cancer in 50 countries around the world. Their conclusions, based on records up to 2017, are that in most high-income countries its incidence continues to increase in young people (under 50 years of age). This increase, however, is not observed in Spain. The results are published in the journal The Lancet Oncology.
Cell-free DNA (cfDNA) sequencing analysis for fetal aneuploidies - chromosomal abnormalities - can incidentally detect maternal cancer, according to a study published in NEJM. Researchers screened 107 pregnant and postpartum mothers with no symptoms of cancer, but who had received unusual clinical cfDNA sequencing results, for cancer. In this sample, cancer was present in 48% of the women.
A study has used geospatial data and satellite imagery to analyze the number of MK 84 bombs dropped by the Israeli army in the Gaza Strip between October 7 and November 17, 2023 that detonated near hospital infrastructure. Of the 36 existing hospitals, 30 of them had suffered at least one explosion within 800 meters. According to the authors of the paper, which is published in PLOS Global Public Health, the research “reveals concerns about indiscriminate shelling near hospital infrastructure, which enjoys special protection under international humanitarian law.”
The use of faecal immunochemical testing (FIT) for colorectal cancer screening is associated with a 33% reduction in the risk of death from colorectal cancer, a study claims. The research, published in JAMA Network Open, analysed data from more than 10,000 people aged 52-85 in the US.
Two studies published in the New England Journal of Medicine evaluate colorectal cancer screening tests that could be alternatives to the existing faecal immunochemical test (FIT), which detects occult blood in stool. The first study uses a new generation test that detects DNA in stool and has a higher sensitivity than FIT, 93.9% for colorectal cancer and 90.6% for advanced neoplasia (tumour formation). The second uses a blood-based DNA detection test with a sensitivity of 83% for colorectal cancer and 90% for advanced neoplasia.